Metabolomic Diagnostics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Metabolomic Diagnostics Ltd. - overview
Established
2011
Location
Cork, -, Ireland
Primary Industry
Healthcare IT
About
Based in Cork, Ireland, and founded in 2011 by co-founders Louise Kenny, Charles Garvey, Diarmuid Cahalane, Robin Tuytten, Ph. D. (CEO), and Paul Hands, Metabolomic Diagnostics Ltd. operates as a provider of a diagnostic platform that develops biomarker-based tests for predicting and preventing complicated diseases to medical institutions and maternal health practitioners.
In September 2024, Trinity Biotech, a portfolio company of DeltaPoint Capital Partners, acquired Metabolomic Diagnostics Ltd. for approximately USD 1. 3 million. The company provides a mass spectrometry-based diagnostic platform that offers advanced biomarker analysis to healthcare providers.
The platform's services include diagnostic testing, data interpretation, and statistical analysis for reliable results. Moreover, the firm offers solutions such as preeclampsia screening and maternal health diagnostics, focusing on early detection of pregnancy-related risks. Additionally, Metabolomic Diagnostics Ltd. also provides predictive testing for complications so that healthcare professionals have access to critical information for improved patient care and outcomes.
Current Investors
Trinity Biotech Plc, Enterprise Ireland, SOSV
Primary Industry
Healthcare IT
Sub Industries
Biopharmaceuticals, Bioinformatics, Healthcare IT
Website
www.metabolomicdiagnostics.com/
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Metabolomic Diagnostics Ltd. - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - | (494,652) | (704,625) | - | - | - | - |
| Operating Income (USD) | - | - | - | - | - | (545,323) | (764,476) | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (43,879) | (127,450) | (286,904) | (605,106) | (827,564) | (545,323) | (764,867) | - | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - |
Metabolomic Diagnostics Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Metabolomic Diagnostics Ltd. | - |
Displaying 1 - 1 of 1
Metabolomic Diagnostics Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.